There are several ongoing research activities and technological developments in accordance with medical research activities which focus on treatment of various ailments. Peptide therapeutics are used to treat several of these ailments, of which metabolic disorders are one type. Peptides possess good stability, efficacy, safety, and moreover, they are small in size, and hence can be easily synchronized. These advantages fuel the growth of the global peptide based metabolic disorders therapeutics market. To support the growth, factors such as technological advancements and increased funding in healthcare, and the impressive business growth of biotech and pharmaceutical companies, have spurred the adoption of the peptides used to treat metabolic disorders. Such disorders have risen, and this has called for a rapid development of therapies based on peptides to treat such disorders. North America is anticipated to show higher attractiveness in the global peptide based metabolic disorders therapeutics market.
A metabolic disorder is a disorder which can occur due to alterations in the normal metabolic processes in the body caused by abnormal chemical reactions take place within. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability. Due to their broad range of mechanisms and activities, they can be used in the treatment of metabolic disorders.
According to Fact.MR’s research report on the global peptide based metabolic disorders therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value more than US$ 8 Bn.
Market Taxonomy
|
Drug |
Distribution Channel |
|
Liraglutide |
Hospital Pharmacies |
|
Exenatide |
Retail Pharmacies |
|
Others |
Online Pharmacies |
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
North America Domination in the Peptide Based Metabolic Disorders Therapeutics
With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share. In terms of revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022. This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market. Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share
APEJ Shows a Similar Growth Rate
The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.
Liraglutide Dominates the Drug Class Category
The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017. However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.
Exenatide and Others Segments Have a Tie
The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast. However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022.
Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth
The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.
Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR
Peptide therapeutics are used to treat metabolic disorders. The global peptide based metabolic disorders therapeutics market is impacted by aspects which link to the various benefits that peptides offer in treating ailments, to name a few, the government regulations to better the healthcare industry, the increasing foreign direct investments, the rising investments in healthcare, and the increasing bio-pharma companies. This Fact.MR report analyzes the expansion of global peptide based metabolic disorders therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.
Scope
The scope of Fact.MR’s report is to analyze the global peptide based metabolic disorders therapeutics market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global peptide based metabolic disorders therapeutics market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide based metabolic disorders therapeutics.
Summary
The report commences with a brief information of the global peptide based metabolic disorders therapeutics market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide based metabolic disorders therapeutics market.
Overview
The next section offers an overview of the global peptide based metabolic disorders therapeutics market. This comprises an introduction to the market, along with a standard definition of the product – peptide based metabolic disorders therapeutics. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period.
The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.
In order to offer readers with up-to-date information about the latest advancements in the global peptide based metabolic disorders therapeutics market, the report provides updates about market opportunities, which can benefit leading manufacturers of peptide based metabolic disorders therapeutics. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for players in the peptide based metabolic disorders therapeutics market to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section.
The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide based metabolic disorders therapeutics market. Drug type, distribution channel and region are key segments that define the growth of the global market for peptide based metabolic disorders therapeutics. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.
The report’s last section comprises of the global peptide based metabolic disorders therapeutics market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide based metabolic disorders therapeutics market.
Research Methodology
Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,
- Primary research
- Secondary research
- Trade research
- Focused interviews
- Social media analysis
1. Global Peptide Based Metabolic Disorders Therapeutics Market - Executive Summary
2. Global Peptide Based Metabolic Disorders Therapeutics Market Overview
2.1. Introduction
2.1.1. Global Peptide Based Metabolic Disorders Therapeutics Market Taxonomy
2.1.2. Global Peptide Based Metabolic Disorders Therapeutics Market Definition
2.2. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
2.2.1. Global Peptide Based Metabolic Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Metabolic Disorders Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region
3. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Drug
3.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
3.1.1. Liraglutide Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.1.1. Revenue (US$ Mn) Comparison, By Region
3.1.1.2. Market Share Comparison, By Region
3.1.1.3. Y-o-Y growth Comparison, By Region
3.1.2. Exenatide Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.2.1. Revenue (US$ Mn) Comparison, By Region
3.1.2.2. Market Share Comparison, By Region
3.1.2.3. Y-o-Y growth Comparison, By Region
3.1.3. Others Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.3.1. Revenue (US$ Mn) Comparison, By Region
3.1.3.2. Market Share Comparison, By Region
3.1.3.3. Y-o-Y growth Comparison, By Region
4. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Distribution Channel
4.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
4.1.1. Hospital Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Retail Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Online Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
5. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Region
5.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.1. North America Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.1.1. Revenue (US$ Mn) Comparison, By Drug
5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.2. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.2.1. Revenue (US$ Mn) Comparison, By Drug
5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.3. Europe Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.3.1. Revenue (US$ Mn) Comparison, By Drug
5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.4. Japan Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.4.1. Revenue (US$ Mn) Comparison, By Drug
5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.5. APEJ Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.5.1. Revenue (US$ Mn) Comparison, By Drug
5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel
5.1.6. MEA Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
5.1.6.1. Revenue (US$ Mn) Comparison, By Drug
5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel
6. North America Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
6.1. US Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
6.1.1. Revenue (US$ Mn) Comparison, By Drug
6.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
6.2. Canada Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
6.2.1. Revenue (US$ Mn) Comparison, By Drug
6.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
7. Latin America Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
7.1. Brazil Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
7.1.1. Revenue (US$ Mn) Comparison, By Drug
7.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
7.2. Mexico Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
7.2.1. Revenue (US$ Mn) Comparison, By Drug
7.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
7.3. Argentina Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
7.3.1. Revenue (US$ Mn) Comparison, By Drug
7.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel
8. Europe Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
8.1. Germany Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
8.1.1. Revenue (US$ Mn) Comparison, By Drug
8.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
8.2. UK Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
8.2.1. Revenue (US$ Mn) Comparison, By Drug
8.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
8.3. France Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
8.3.1. Revenue (US$ Mn) Comparison, By Drug
8.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel
8.4. Spain Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
8.4.1. Revenue (US$ Mn) Comparison, By Drug
8.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel
8.5. Italy Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
8.5.1. Revenue (US$ Mn) Comparison, By Drug
8.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel
8.6. Nordic Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
8.6.1. Revenue (US$ Mn) Comparison, By Drug
8.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel
9. Japan Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
9.1. Japan Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
9.1.1. Revenue (US$ Mn) Comparison, By Drug
9.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
10. APEJ Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
10.1. China Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
10.1.1. Revenue (US$ Mn) Comparison, By Drug
10.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
10.2. India Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
10.2.1. Revenue (US$ Mn) Comparison, By Drug
10.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
10.3. Malaysia Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
10.3.1. Revenue (US$ Mn) Comparison, By Drug
10.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel
10.4. Thailand Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
10.4.1. Revenue (US$ Mn) Comparison, By Drug
10.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel
10.5. Singapore Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
10.5.1. Revenue (US$ Mn) Comparison, By Drug
10.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel
10.6. Australia Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
10.6.1. Revenue (US$ Mn) Comparison, By Drug
10.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel
11. MEA Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
11.1. GCC Countries Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
11.1.1. Revenue (US$ Mn) Comparison, By Drug
11.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel
11.2. South Africa Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
11.2.1. Revenue (US$ Mn) Comparison, By Drug
11.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel
11.3. Nigeria Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
11.3.1. Revenue (US$ Mn) Comparison, By Drug
11.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel
11.4. Israel Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
11.4.1. Revenue (US$ Mn) Comparison, By Drug
11.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel
12. Global Peptide Based Metabolic Disorders Therapeutics Market Competition Landscape and Company Profile
12.1. Company Share Analysis By Region
12.2. AstraZeneca plc
12.2.1. Company Overview
12.2.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.2.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.3. Bachem Holding AG
12.3.1. Company Overview
12.3.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.3.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.4. CordenPharma International
12.4.1. Company Overview
12.4.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.4.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.5. Eli Lilly and Company
12.5.1. Company Overview
12.5.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.5.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.6. Ipsen S.A
12.6.1. Company Overview
12.6.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.6.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.7. Merck & Co., Inc
12.7.1. Company Overview
12.7.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.7.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.8. Novo Nordisk A/S
12.8.1. Company Overview
12.8.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.8.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.9. PolyPeptide Group
12.9.1. Company Overview
12.9.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.9.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.10. Teva Pharmaceutical Industries Ltd
12.10.1. Company Overview
12.10.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
12.10.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
12.10.4. Key Developments
12.10.5. SWOT Analysis
13. Research Methodology
14. Secondary and Primary Sources
15. Assumptions and Acronyms
16. Disclaimer
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.
Our Clients
Fact.MR in Media
Our analysts in Media
Peptide Based Metabolic Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022